Comparison of Strontium Ranelate and Alendronate Sodium Treatment among Post-Menopausal Women

Abstract

Growing rates of osteoporosis in the whole world is a serious health problem. As the "expected lifetime" is prolonged, population of elderly women with chronic diseases who require long-term treatment increases. This study aimed to compare antiresorptive treatment-that has become a classic treatment in the light of Canadian Guideline for osteoporosis-with the antiresorptive plus osteoblastic activity inducing treatment modality. The clinical and laboratory results of patients treated with a single dose of 2 mg Strontium ranelate sachet (Protelos ®) or alendronate sodium used weekly 70 mg tablet (Fosamax ® once a week tablet) for 12-months were compared. Treatment compliance has been questioned. A hundred women in post-menopausal period were included in this study. Patient satisfaction survey among the group of strontium ranelate was unsatisfactory. Among patients using alendronate sodium the ease of use in this sense obtained a rate of 91% satisfaction from patients.

Synthesis of a Calcium Silicate Cement Containing a Calcinated Strontium Silicate Phase

“…Also, incorporation of strontium in bone and dental cements can induce the differentiation of mesenchymal stem cells in bone and teeth [ 9 ]. The bioavailability of orally taken strontium ions is only 20% [ 10 ]. Thus, local release of strontium ions at the bone defect site is preferred compared with increasing the oral dosage of strontium.…”